A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study aims to identify the safety and tolerability of bile acid supplementation in
patients with progressive Multiple Sclerosis (MS). Participants will also be assessed for an
impact of the bile acid on their immune system and gut microbiome. Half of the participants
will receive the bile acid tauroursodeoxycholic acid (TUDCA) and half will receive placebo.
The investigators believe participants who take TUDCA will have normalization of blood bile
acid levels, a normalization of abnormal immune response and a normalization of the gut
microbiome.